Nuvaring Insert, Extended Release
Product Images NDC 50090-7663

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Nuvaring (NDC 50090-7663). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907663)

NUVARING vaginal insert extended release label from A-S Medication Solutions. The label includes the active ingredients etonogestrel and ethinyl estradiol with strengths of .015 mg and .12 mg per day. The product is supplied as an extended release vaginal insert containing one ring, with storage instructions to avoid direct sunlight and heat. The label also notes that the product is for human prescription use and includes the product NDC 50090-7663-01.*

FDA Label Image

Figure 1 (Nuvaring 01)

A horizontal bar chart showing the number of women with a blood clot out of 10,000 woman-years categorized by four groups: Non-CHC users who are non-pregnant, CHC users, pregnant women, and postpartum women (12 weeks only). Each bar is divided into two segments indicating ranges of risk, with postpartum women having the highest range shown.*

FDA Label Image

Figure 2 (Nuvaring 01a)

A forest plot chart comparing various studies on contraceptive use and effect estimates. The plot includes multiple horizontal lines and points with confidence intervals for effect estimates such as odds ratios (OR), risk ratios (RR), and hazard ratios (HR) against a horizontal axis labeled from -1.50 to 2.00. Studies cited include NICHD Women's Care Study, French E3N cohort Study, Shanghai Women's Health Study, Nurses' Health Study, Oxford Family Planning Study, and Danish Sex Hormone Register Study.*

FDA Label Image

Chemical Structure (Nuvaring 02)

Chemical structures of the active ingredients etonogestrel and ethinyl estradiol, showing their molecular formulas C22H28O2 and C20H24O2 respectively. The diagrams depict the steroid backbone with attached functional groups for each compound.*

FDA Label Image

Figure 3 (Nuvaring 03)

A line graph showing plasma concentration levels of etonogestrel and ethinyl estradiol (EE) over 21 days following NuvaRing insertion. Etonogestrel levels rise sharply and then plateau near 1500 pg/mL, while ethinyl estradiol levels remain low around 20 pg/mL throughout the period.*

FDA Label Image

Figure 3 (Nuvaring 04)

An infographic showing the relative effectiveness of various birth control methods, with an arrow indicating the range from fewer to more pregnancies per 100 women per year. Methods with fewer pregnancies include implants, injections, intrauterine devices, and sterilization. Mid-range methods include birth control pills, skin patch, and vaginal ring with hormones. Condoms and diaphragm are in a higher pregnancy rate category. Behavioral methods like avoiding sex during fertile days, spermicide, and withdrawal show more pregnancies. No birth control corresponds to the highest pregnancy rates.*

FDA Label Image

Figure 4 (Nuvaring 05)

A horizontal bar chart comparing the number of women with a blood clot out of 10,000 woman-years among four groups: Non-CHC* users who are non-pregnant, CHC users, pregnant women, and postpartum women within 12 weeks. Each group shows a range with two segments in the bars indicating different sub-ranges for blood clot incidence.*

FDA Label Image

Figure A, Figure B, Figure C (Nuvaring 06)

Instructional illustration showing three figures demonstrating different postures. Figure A depicts a person lying on their back with knees bent. Figure B shows a person sitting with knees drawn up. Figure C illustrates a person standing and lifting one leg onto a step or elevated surface. The images appear to guide positioning or insertion techniques related to the vaginal insert dosage form.*

FDA Label Image

Figure D, Figure E (Nuvaring 07)

Illustrations showing two hands handling the NUVARING vaginal insert. Figure D displays a hand holding the ring between thumb and forefinger, while Figure E shows a hand pinching and squeezing the ring with thumb and forefinger, likely demonstrating insertion technique.*

FDA Label Image

Figure F (Nuvaring 08)

An anatomical illustration showing the placement of NuvaRing, a vaginal insert, inside the female reproductive system. The diagram labels the uterus, vagina, and NuvaRing positioned within the vagina.*

FDA Label Image

Figure G (Nuvaring 09)

An instructional anatomical diagram showing the vaginal insertion of the NUVARING contraceptive insert. The image illustrates a hand placing the flexible ring inside the vaginal canal adjacent to the cervix, demonstrating proper placement for vaginal administration.*

FDA Label Image

Figure H (Nuvaring 10)

An anatomical illustration showing the female reproductive system in a sagittal view, highlighting the vaginal canal where a NuvaRing vaginal insert is positioned. The diagram provides a visual guide to the placement of the extended-release contraceptive ring inside the vagina.*

FDA Label Image

Figure I (Nuvaring 11)

An anatomical illustration showing the female pelvic side view with a vaginal insert positioned inside. This diagram likely demonstrates the placement or use of a vaginal extended-release insert, such as NUVARING, containing etonogestrel and ethinyl estradiol.*

FDA Label Image

Figure J (Nuvaring 12)

An instructional anatomical illustration showing the vaginal insertion of the NUVARING vaginal insert using a hand, depicting the proper placement within the vaginal canal.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.